Role Of Myo-Inositol Supplementation in prevention of Gestational Diabetes Mellitus in parturient women at risk.

  • Anam Mumtaz PIMS
  • Ainy Senior Registrar MCH Centre, Unit 1,Pakistan Institute of Medical Sciences,Islamabad.
  • Musarrat Batool Assistant Professor,MCH Centre, Unit 1Pakistan Institute of Medical Sciences Islamabad 
  • Shirza Sharafat Ali Senior Registrar MCH Center, Unit I Pakistan Institute of Medical Sciences Islamabad 
Keywords: Gestational diabetes, Myo-Inositol supplementation


Introduction: Several inositol isomers and in particular Myo-inositol (MI) is shown to be efficient in lowering post-prandial blood glucose. Myo-inositol can be found in pulses, nuts, and fruits (in particular citrus fruits). Initial evidence shows reduction in gestational diabetes by up to 60% as the effect of Myo-inositol supplementation. This study aimed to assess frequency of Gestational Diabetes Mellitus in parturient women at risk after supplementation of Myo-Inositol as compared to placebo.
Methodology: This Randomized Controlled trial was conducted in the Outpatient Department of Obstetrics and Gynecology, PIMS, Islamabad from 15th July 2020 to 14th January 2021. A total 120 pregnant women irrespective of parity in first trimester having: 1 or more first-degree relative diagnosed with diabetes mellitus, who were overweight (BMI >25 kg/m2) or Obese (BMI >30 kg/m2) at their first antenatal visit were selected. Women with already diagnosed with Diabetes Mellitus were excluded. Starting from the end of first trimester or start of second trimester (12-15 weeks of gestation) the intervention group was supplemented with 2g Myo-Inositol and 200 mcg Folic acid twice daily as compared to placebo which was given only 200 mcg Folic acid twice daily. Between 24-48 weeks, they were tested for 75gm 2 hour OGTT. Ethical clearance was taken and written informed consent was administered.
Results: The mean age of women in interventional group was 27.78 ± 4.07 years and in placebo group was 28.88 ± 4.19 years. The mean gestational age was 9.33 ± 1.90 weeks in intervention and 9.52 ± 1.85 weeks in the placebo group. In this study, the frequency of Gestational Diabetes Mellitus in parturient women at risk after supplementation of Myo-Inositol was 16.67% as compared to 36.67% in placebo (p-value, 0.01).
Conclusion: Myo-Inositol supplementation reduces the rate of development of GDM in pregnant women having known risk factors.

Original Articles